Philips Beats Q3 Estimates, Lifts Free Cash Flow Outlook on Tariff Refund
PHG sits 22% above its 52-week low of $23.62.
Summary
Philips beat on both lines for Q3: adjusted earnings of 46 cents versus 37 cents consensus, and sales of $5.06 billion versus $4.99 billion expected. Comparable sales rose 3% with 8% order intake growth, and the adjusted EBITA margin expanded to 13.0% on higher gross margin and productivity measures. Operating income fell 50% to 165 million euros because of a 288-million-euro provision for the Respironics settlement with the U.S. Department of Justice, with payment expected in Q1 2027. The company reiterated its 2026 sales and margin outlook and raised free cash flow guidance to 1.5-1.7 billion euros from 1.3-1.5 billion to reflect a 200-million-euro U.S. tariff refund. Shares were up 6.05% at $29.26 premarket. This lands after the October 9 FDA safety alert on the Lumify ultrasound system, and Diagnosis & Treatment comparable sales were flat on ultrasound phasing and weaker China sales.
At the time of this announcement, PHG was trading at $28.87 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26.7B. The 52-week trading range was $23.62 to $33.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.